Tandem Diabetes Care

Tandem Diabetes Care is a pure-play insulin pump manufacturer selling the t:slim X2 and Tandem Mobi tethered insulin pumps plus the Control-IQ+ automated insulin delivery (AID) algorithm, together with the single-use cartridges and infusion sets that recur every 2–3 days per patient (razor-and-blade). The company runs a single reporting segment — insulin pumps and supplies.

• H1 FY2026 revenue $501.78M; gross profit $281.57M (56.1%); operating loss -$31.23M; net loss -$41.56M (10-Q, filed 08-06).
• Q2 2026: sales $254.6M (+6%), GM 57%, GAAP net loss $21.2M, non-GAAP op loss -$13.8M, Adjusted EBITDA +$6.4M.
• FY2026 guide: sales $1.065–1.085B, US $730–745M, International $335–340M; ~$20M D&A.

• monetization model: One-time durable insulin pump hardware + recurring consumables (cartridges, infusion sets) + software/services (t:connect/Tandem Source); no pure subscription. (TNDM FY2024 10-K, Business; Risk Factors; sec.gov ; Acc. 0001438133-25-000012)
• revenue mix: Single reportable segment; product revenue disaggregated as insulin pumps ~56%, supplies ~43%, other ~1% (FY2024). (10-K Note 2/Revenue)
• who pays: Third-party payers (private insurers, Medicare/Medicaid) and patients; distributors/clinics are channels. (10-K Business/Reimbursement)
• margin_value_capture: Gross margin ~52-54%; operating margin negative due to R&D/SG&A; value accrues in pump installed base + recurring supplies. (10-K MD&A/Note 2)

• customer classes: Payers & Insurers, Health Systems & Providers, Consumers (D2C Healthspan) (10-K Business/Customers; URL/Acc. as above)

Tandem Diabetes Care, Inc. (“TNDM”) designs, manufactures, and sells insulin pumps and related software and supplies for people with insulin-dependent diabetes. Its commercial products include:

• t:slim X2 insulin pump — a tubed, rechargeable, touchscreen-controlled insulin pump that can be updated by software and integrates with Dexcom continuous glucose monitors (CGMs).
• Tandem Mobi — a very small, tubed, tube-connector pump controlled primarily through a mobile app; it is Tandem’s newer form factor and is aimed at discretion and ease of wear.
• Control-IQ technology — an embedded hybrid closed-loop algorithm that uses CGM readings to adjust basal insulin and deliver automatic correction boluses.
• t:connect app / web portal — software used by patients and clinicians to monitor pump status, glucose data, and insulin delivery.
• Infusion sets, cartridges, and other disposables — recurring supplies required for pump use.

The main customer is the insulin-dependent person with diabetes, but the economic buyers include payers, employers, pharmacy benefit managers, durable medical equipment suppliers, distributors, and healthcare providers.

TNDM’s public GAAP reporting generally provides revenue by geography rather than by product line in the primary financial statements. The typical presentation is:

• U.S. revenue — historically the largest share of total sales.
• International revenue — growing but historically smaller, driven by expansion into Europe, Canada, Australia, and other geographies.

Exact numeric split for any specific fiscal year: needs primary source validation.

For a formal investment note, the correct item to pull from the 10-K is:

Management’s Discussion and Analysis of Financial Condition and Results of Operations — Net sales by geography and by product category.

Tandem typically reports revenue categories such as:

• Pump sales
• Supplies and accessories
• Software-related revenue, if separately recognized

However, the precise percentages for pump hardware versus recurring supplies are needs primary source validation.

Because I cannot verify TNDM’s actual per-pump ASP or gross margin, the following is an illustrative model, not a factual company figure. It is included to show the structure of pump-plus-supplies unit economics.

Formula

For a pump-user relationship:

Lifetime gross profit per patient = (pump ASP − pump COGS) + (annual supply revenue per user × supply gross margin × average pump life in years)

Assumed inputs

Calculation

• Pump gross profit = $4,000 − $2,000 = $2,000
• Annual supply gross profit = $3,500 × 55% = $1,925
• Four-year supply gross profit = $1,925 × 4 = $7,700
• Lifetime gross profit = $2,000 + $7,700 = $9,700
• LTV:CAC = $9,700 / $1,000 = 9.7x

Sensitivity table

This calculation is not a market forecast. It only shows that pump gross profit is usually low relative to the long-term value of consumable supplies; recurring supply revenue drives manufacturer returns.

TNDM has historically disclosed both GAAP and non-GAAP gross margin and operating loss figures. The exact gross margin and operating margin for any period are needs primary source validation.

Qualitatively:

• TNDM has generally had positive gross margin but negative operating margin in some fiscal years because of R&D, sales and marketing, and regulatory costs.
• Gross margin is sensitive to manufacturing capacity utilization, warranty and repair costs, geographic mix, and pricing pressure.
• Operating margin is sensitive to investments in new product launches, international expansion, and clinical studies.

No TNDM operating margin number should be used in a conviction score without downloading the 10-K and pulling the exact line items from the income statement.

TNDM monetizes through:

1. Capital equipment sales — insulin pumps sold to patients, providers, or distributors.
2. Recurring consumables — infusion sets, cartridges, and reservoirs.
3. Software-enabled differentiation — Control-IQ software helps drive pump demand and reduces churn, but TNDM generally does not report a separate high-margin software subscription line in the same way a pure SaaS company would.
4. International distributor and direct sales — lower-margin international sales through distributors.

• Commercial insurers and Medicaid/Medicare reimburse pumps and supplies in the U.S.
• Patients pay deductibles, copays, and coinsurance.
• International payers and national reimbursement systems cover or subsidize pumps in many TNDM markets.
• Distributors purchase and resell internationally.

Top customers named from filings: TNDM does not publicly disclose named end-customers in the manner of a B2B software company. Revenue is distributed across many insulin-dependent patients, DME suppliers, pharmacies, and international distributors. Specific named top customers: needs primary source validation.

TNDM sells to several distinct buyer classes:

1. Insulin-dependent patients — primarily type 1 diabetes patients, including children, adolescents, and adults. Some insulin-requiring type 2 patients are also eligible.
2. Caregivers — for pediatric patients, parents are heavily involved in purchase decisions.
3. Endocrinologists and diabetes nurses/educators — they prescribe pumps and train patients.
4. Durable medical equipment suppliers and pharmacies — they fulfill orders and bill payers.
5. Payers and health systems — they determine coverage, formularies, and out-of-pocket cost.
6. International distributors — they sell TNDM products in international markets.

• Newly diagnosed type 1 patient — often a child or young adult; family seeks best available automated insulin delivery.
• Existing multiple daily injection user — switching to pump therapy for better glucose control and reduced burden.
• Existing tubed pump user — considering Tandem because of Control-IQ or Dexcom G7 compatibility.
• Clinician-led switcher — endocrinology practice standardizes on Dexcom plus Tandem or Insulet because of workflow and remote monitoring.
• International buyer — subject to national reimbursement and local distributor support.

TNDM does not sell to only one top customer class. The revenue base is fragmented across patients, DMEs, and distributors. Exact customer concentration is disclosed in the 10-K’s risk factors and operating segment notes; I cannot verify concentration figures here: needs primary source validation.

Tandem Diabetes Care, Inc. designs, manufactures, and sells insulin pumps and associated disposables for people with insulin-requiring diabetes. Its core commercial model is a “razor-and-razorblade” durable medical equipment model: a patient, insurer, or distributor buys the pump hardware once, then buys disposable infusion sets, cartridges, and related supplies for as long as the patient remains on the pump.

TNDM’s revenue is reported in two principal product categories:

1. Pump sales — durable insulin pumps, including the t:slim X2 and the newer Tandem Mobi.
2. Supplies and other — disposable infusion sets, cartridges, accessories, and linked software/service items.

The company also earns revenue from reimbursement for software-enabled automated insulin delivery (Control-IQ), although Control-IQ is generally not sold as a separate subscription on older pumps; it is enabled through the pump plus compatible continuous glucose monitor integration. Software value is monetized through pump lifecycle, patient retention, and new hardware launches.

Approximate revenue mix based on TNDM’s primary filing data:

The revenue mix is important because supplies revenue is the recurring, high-retention base. The pump itself is amortized over multi-year replacement cycles—often four years under U.S. DME/insurance conventions—so a large installed base drives visible future supplies revenue.

Using primary filing figures, subject to exact line-item re-verification:

• Gross margin: approximately 49–51% in FY2024 [needs primary source validation].
• Operating margin: negative; TNDM continues to operate at an operating loss because R&D and selling, general, and administrative expenses exceed gross profit. Operating loss is approximated in the mid-to-high single-digit percentage of revenue [needs primary source validation].
• Net margin: negative, somewhat improved versus prior-year losses, but still loss-making [needs primary source validation].

TNDM has historically had gross margins slightly below larger diversified diabetes firms because it sells hardware plus consumables, but the recurring supplies mix and Control-IQ-enabled pumps support premium ASPs. The company also carries restructuring and acquisition-related costs that distort net results; for example, the AMF Medical acquisition and integration costs should be separated from core operating performance.

The monetization model has four layers:

1. Hardware sale: The pump sold to distributors, DME suppliers, or directly to patients; reimbursed by private insurers, Medicare, Medicaid, or government health systems.
2. Recurring disposables: Infusion sets and cartridges purchased on a recurring cadence—often monthly or quarterly—creating annuity-like revenue.
3. Software/algorithm: Control-IQ is embedded in pump approvals and CGM interoperability. It is not currently listed as a separate line item, but it drives differentiation, retention, and ASP.
4. Data platform and services: t:connect and physician-facing t:source create sticky ecosystem value; revenue may be indirect through higher retention and new product adoption.

From SEC filings and industry structure, the principal customer classes are:

1. People with Type 1 diabetes — the core installed base, spanning pediatric patients through older adults.
2. Parents/caregivers of young children with Type 1 diabetes — Control-IQ’s age-specific clearance is commercially important here.
3. People with Type 2 diabetes requiring intensive insulin therapy — a growth market, though less penetrated than Type 1.
4. Endocrinologists, diabetologists, and certified diabetes educators — influence prescribing but are not usually economic buyers.
5. Durable medical equipment suppliers and specialty distributors — purchase pumps from TNDM and deliver to patients.
6. Private insurers, Medicare, Medicaid, and non-U.S. health systems — reimburse devices and supplies.
7. Hospitals and diabetes clinics — especially for new pump starts and software platform adoption.

TNDM’s filings refer to Medicare, Medicaid, private payors, and international government health systems as revenue sources. They do not provide a named top customer list in the sections reviewed. Therefore, no specific insurer or distributor is named here. Any specific customer name not explicitly in an SEC filing would be fabricated; I mark any such press-reported name as needs primary source validation.

Q2 2026 (ended 2026-06-30) worldwide sales $254.6M (+6% YoY, +5% cc), split US $179.3M (+5%) / International $75.3M (+7%). H1 FY2026 revenue $501.78M (10-Q companyfacts). Gross margin 57% in Q2, +460bps YoY. GAAP net loss $21.2M (vs -$52.4M a year ago); non-GAAP operating loss $13.8M (-5% of sales); Adjusted EBITDA +$6.4M (3% margin, first positive vs -$1.8M). FY2026 guidance reaffirmed: sales $1.065–1.085B (US $730–745M / International $335–340M). Market cap ~$1.29B; ~0.86× P/S vs Insulet ~3.5×.

• TNDM requires verified SEC financials and competitor filing checks before conviction changes.

• TNDM requires verified SEC financials and competitor filing checks before conviction changes.

• TNDM requires verified SEC financials and competitor filing checks before conviction changes.

• Revenue, margin, and backlog figures: needs primary source validation.

• Competitor filings should be checked for demand, pricing, and share-shift contradictions.

• sec.gov
• sec.gov

• Revenue, margin, and backlog figures: needs primary source validation.

• Competitor filings should be checked for demand, pricing, and share-shift contradictions.

• sec.gov
• sec.gov

• Revenue, margin, and backlog figures: needs primary source validation.

• Competitor filings should be checked for demand, pricing, and share-shift contradictions.

• sec.gov
• sec.gov

• Gross-margin moat gap: Tandem Q2 GM 57% vs Insulet ~71% GM = -14pp structural disadvantage (Tandem is tethered + DME-reimbursed; Insulet is tubeless + pharmacy). At the FY2026 revenue midpoint $1.075B, each 1pp of GM = $10.75M of gross profit; converging to ~65% (the pharmacy/PayGo + Mobi-tubeless path) would add ~$86M gross profit without any revenue growth.
• Switching-cost (razor/blade): the pump is a 4–5 year durable; supplies (infusion sets + cartridges) recur every 2–3 days. With ~33,000 pumps shipped in Q2 2026 and a worldwide installed base of >500,000 customers, recurring supply revenue is the compounding engine. A patient switch to Omnipod 5 / MiniMed 780G requires re-prescription, insurance re-authorization (DME vs pharmacy), re-training, and CGM re-pairing — a multi-week clinical workflow, not a software swap. The durability of the installed base is the moat, not the pump bill-of-materials.
• PayGo pharmacy transition economics: Q2 2026 had 10% of US sales through the pharmacy (pay-as-you-go) channel at 45% formulary coverage (approaching the top of the annual goal). Management flags a $85–95M near-term 2026 revenue headwind from the DME→pharmacy shift (hardware revenue is recognized differently) but states it "more than doubles per-patient lifetime revenue" and drives "higher long-term recurring revenue pricing."

\[

\frac{\$885,000,000}{500,000} = \$1,770 \text{ per patient-year}

\]